02030nam 2200457 450 991071532750332120210304110643.0(CKB)5470000002510762(OCoLC)1240422157(EXLCZ)99547000000251076220210304d2021 ua 0engur|||||||||||txtrdacontentcrdamediacrrdacarrierDrug safety: FDA's future inspection plans need to address issues presented by COVID-19 backlog testimony before the Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, Committee on Appropriations, House of Representatives /statement of Mary Denigan-Macauley[Washington, D.C.] :United States Government Accountability Office,2021.1 online resource (18 pages) color illustrations, color mapTestimony ;GAO-21-409T"For release on delivery, expected at 10:00 a.m. ET, Thursday, March 4, 2021."Includes bibliographical references.Drug safetyCOVID-19 (Disease)TreatmentUnited StatesCOVID-19 Pandemic, 2020-United StatesDrugsInspectionUnited StatesDrugsUnited StatesSafety measuresDrug reimportationUnited StatesCOVID-19 (Disease)TreatmentCOVID-19 Pandemic, 2020-DrugsInspectionDrugsSafety measures.Drug reimportationDenigan-Macauley MaryUnited States.Congress.House.Committee on Appropriations.Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies,GPOGPOBOOK9910715327503321Drug safety: FDA's future inspection plans need to address issues presented by COVID-19 backlog3523347UNINA